IgA-нефропатия: прогнозирование рисков прогрессирования

Иммуноглобулин А-нефропатия (англ. immunoglobulin A, IgA) является наиболее распространенной формой хронического гломерулонефрита и одной из ведущих причин терминальной почечной недостаточности. В настоящее время возможности точного прогнозирования риска прогрессирования данной патологии на уровне отдельных пациентов ограничены. В статье проведен анализ научной литературы, содержащей результаты исследований, посвященных определению независимых предикторов риска про грессирования IgA-нефропатии. Согласно результатам большинства исследований такие переменные, как протеинурия, артериальная гипертензия и исходная функция почек, имеют устойчивую и независимую связь с ухудшением почечного прогноза. Гистологические изменения в нефробиоптате выступают как отдельные предикторы. Сочетание морфологических и клинических данных позволяет повысить точность прогнозирования. Для улучшения результатов лечения и отдаленных исходов необходимы дальнейшие исследования, включая поиск новых биомаркеров и разработку общепринятой системы стратификации риска.

1. Шилов Е.М., Смирнов А.В., Козловская Н.Л. (ред.) Нефрология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2016: 816 с.

2. Бобкова И.Н., Буланов Н.М., Захарова Е.В. и др. Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней. Нефрология и диализ. 2022; 24 (4): 577–874. https://doi.org/10.28996/2618-9801-2022-4-577-874.

3. Schena F.P., Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018; 38 (5): 435–42. https://doi.org/10.1016/j.semnephrol.2018.05.013.

4. Soares M.F. An update on pathology of IgA nephropathy. J Bras Nefrol. 2016; 38 (4): 435–40. https://doi.org/10.5935/0101-2800.20160069.

5. Riispere Ž., Laurinavičius A., Kuudeberg A., et al. IgA nephropathy clinicopathologic study following the Oxford classification: progression peculiarities and gender-related differences. Medicina. 2016; 52 (6): 340–8. https://doi.org/10.1016/j.medici.2016.11.003.

6. Kiryluk K., Freedberg D.E., Radhakrishnan J., et al. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023; 4 (8): 1112–22. https://doi.org/10.34067/KID.0000000000000165.

7. Yamada K., Doi S., Nakashima A., et al. Expression of age-related factors during the development of renal damage in patients with IgA nephropathy. Clin Exp Nephrol. 2015; 19 (5): 830–7. https://doi.org/10.1007/s10157-014-1070-2.

8. Sato Y., Tsukaguchi H., Higasa K., et al. Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a singlecenter longitudinal study. BMC Nephrol. 2021; 22 (1): 230. https://doi.org/10.1186/s12882-021-02425-8.

9. Barbour S.J., Coppo R., Zhang H., et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019; 179 (7): 942–52. https://doi.org/10.1001/jamainternmed.2019.0600.

10. Coppo R., Troyanov S., Bellur S., et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86 (4): 828–36. https://doi.org/10.1038/ki.2014.63.

11. Mohd R., Mohammad Kazmin N.E., Abdul Cader R., et al. Long term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One. 2021; 16 (4): e0249592. https://doi.org/10.1371/journal.pone.0249592.

12. Tang C., Chen P., Si F.L., et al. Time-varying proteinuria and progression of IgA nephropathy: a cohort study. Am J Kidney Dis. 2024; 84 (2): 170–8e1. https://doi.org/10.1053/j.ajkd.2023.12.016.

13. Le W., Liang S., Hu Y., et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012; 27 (4): 1479–85. https://doi.org/10.1093/ndt/gfr527.

14. Li X., Liu Y., Lv J., et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014; 9 (3): 484–9. https://doi.org/10.2215/CJN.01990213.

15. Shirai S., Yasuda T., Kumagai H., et al. Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis (a multicenter cohort study). Clin Exp Nephrol. 2023; 27 (4): 340–8. https://doi.org/10.1007/s10157-023-02316-2.

16. Berthoux F., Mohey H., Laurent B., et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011; 22 (4): 752–61. https://doi.org/10.1681/ASN.2010040355.

17. Soleymanian T., Najafi I., Salimi B.H., Broomand B. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in Iran. Ren Fail. 2011; 33 (6): 572–7. https://doi.org/10.3109/0886022X.2011.585001.

18. Wakai K., Kawamura T., Endoh M., et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006; 21 (10): 2800–8. https://doi.org/10.1093/ndt/gfl342.

19. Geddes C., Rauta V., Gronhagen-Riska C., et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003; 18 (8): 1541–8. https://doi.org/10.1093/ndt/gfg207.

20. Chen D., Liu J., Duan S., et al. Clinicopathological features to predict progression of IgA nephropathy with mild proteinuria. Kidney Blood Press Res. 2018; 43 (2): 318–28. https://doi.org/10.1159/000487901.

21. Weng M., Lin J., Chen Y., et al. Time-averaged hematuria as a prognostic indicator of renal outcome in patients with IgA nephropathy. J Clin Med. 2022; 11 (22): 6785. https://doi.org/10.3390/jcm11226785.

22. Sevillano A., Gutiérrez E., Yuste C., et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017; 28 (10): 3089–99. https://doi.org/10.1681/ASN.2017010108.

23. Добронравов В.А. Мужецкая Т.О., Лин Д.И., Кочоян З.Ш. Иммуноглобулин А-нефропатия в российской популяции: клиникоморфологическая презентация и отдаленный прогноз. Нефрология. 2019; 23 (6): 45–60. https://doi.org/10.36485/1561-6274-2019-23645-60.

24. Tanaka S., Ninomiya T., Katafuchi R., et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013; 8 (12): 2082–90. https://doi.org/10.2215/CJN.03480413.

25. Heybeli C., Oktan M.A, Yıldız S., et al. Clinical significance of mesangial IgM deposition in patients with IgA nephropathy. Clin Exp Nephrol. 2019; 23 (3): 371–9. https://doi.org/10.1007/s10157-0181651-6.

26. Zeng C.H., Le W., Ni Z., et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis. 2012; 60 (5): 812–20. https://doi.org/10.1053/j.ajkd.2012.06.011.

27. Walsh M., Sar A., Lee D., et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol. 2010; 5 (3): 425-30. https://doi.org/10.2215/CJN.06530909.

28. Manno C., Strippoli G.F, D'Altri C., et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007; 49 (6): 763–75. https://doi.org/10.1053/j.ajkd.2007.03.013.

29. Yau T., Korbet M., Schwartz M.M., et al. The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol. 2011; 34 (5): 435–44. https://doi.org/10.1159/000332223.

30. Lv J., Shi S., Xu D., et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62 (5): 891–9. https://doi.org/10.1053/j.ajkd.2013.04.021.

31. Alamartine E., Sauron С., Laurent B., et al. Use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011; 6 (10): 2384–8. https://doi.org/10.2215/CJN.01170211.

32. Reich H.N., Troyanov S., Scholey J.W., et al. Toronto Glomerulonephritis Registry: remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18 (12): 3177– 83. https://doi.org/10.1681/ASN.2007050526.

33. Bobart S.A., Alexander M.P., Shawwa K., et al. The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2021; 36 (5): 840–7. https://doi.org/10.1093/ndt/gfz267.

34. Schimpf J.I., Klein T., Fitzner C., et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrol. 2018; 19 (1): 328. https://doi.org/10.1186/s12882-018-1128-6.

35. Alamartine E., Sabatier J.C., Berthoux F.C. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol. 1990; 34 (2): 45–51.

36. Sakai H., Abe K., Kobayashi Y., et al. Clinical guidelines of IgA nephropathy. Nihon Jinzo Gakkai Shi. 1990; 37 (8): 417–21.

37. Lee S.M.K., Rao V.M., Franklin W.A., et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982; 13 (4): 314–22. https://doi.org/10.1016/s0046-8177(82)80221-9.

38. Thompson A., Carroll K.A., Inker L., et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019; 14 (3): 469–81. https://doi.org/10.2215/CJN.08600718.

39. Cravedi P., Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013; 76 (4): 516–23. https://doi.org/10.1111/bcp.12104.

40. Huang Z., Wen Q., Zhou S.F., Yu X.Q. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome. Cytokine. 2008; 42 (2): 222–33. https://doi.org/10.1016/j.cyto.2008.02.005.

41. Barbour S., Reich H. An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens. 2018; 27 (3): 214–20. https://doi.org/10.1097/MNH.0000000000000405.

42. Coppo R., D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005; 18 (5): 503–12.

43. Roberts I.S., Cook H.T., Troyanov S., et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76 (5): 546–56. https://doi.org/10.1038/ki.2009.168.